This new classification includes GBM in the diffuse astrocytic and oligodendroglial tumors group and divides it into three subgroups based on isocitrate dehydrogenase (IDH) mutations: 1) glioblastoma, IDH‐wildtype, clinically identified as primary GBM or de novo GBM and predominant in patients over 55 years of age (10% of cases), 2) glioblastoma, IDH‐mutant, clinically identified as secondary GBM and more common in younger patients (90% of cases), and 3) glioblastoma NOS (not otherwise specified), which does not fit into the other categories and is not well defined (Table1). This evidence concerns the gene IDH2 and glioblastoma.